以c-Met为肿瘤治疗靶点的受体酪氨酸激酶抑制剂的研究进展

发布时间：2018-08-28 11:12

【摘要】：受体酪氨酸激酶c-Met在细胞的增殖、代谢以及肿瘤的产生、转移、血管生成中扮演着重要角色,c-Met成为抗肿瘤治疗的重要靶点。HGF/c-Met信号通路与VEGFR等其他通路的相互作用(cross-talk)影响了抗肿瘤药物的作用效果,产生耐药性,因此,多激酶靶点联合用药成为新的抗肿瘤治疗手段。本文介绍了c-Met信号通路与多种膜受体间的相互作用以及由这种相互作用引起的对激酶抑制剂的耐药性,并综述了单靶点和多靶点的小分子c-Met抑制剂的研究进展。
[Abstract]:Receptor tyrosine kinase c-Met is involved in cell proliferation, metabolism, tumorigenesis and metastasis. Angiogenesis plays an important role in anti-tumor therapy. The interaction between c-Met signaling pathway and other pathways such as VEGFR (cross-talk) affects the effect of anti-tumor drugs and results in drug resistance. The combination of multi-kinase targets has become a new anti-tumor therapy. In this paper, the interaction between c-Met signaling pathway and multiple membrane receptors and the resistance to kinase inhibitors caused by this interaction are reviewed, and the research progress of single-target and multi-target small molecular c-Met inhibitors is reviewed.
【作者单位】：中国药科大学药物化学教研室;
【分类号】：R943

【共引文献】